ERBB2 and neoplasm: Patients with ctDNA detected at baseline exhibited significantly higher rates of advanced clinical tumor stages (p = 0.004), clinical nodal stages (p = 0.03), and HER2-positive tumors (p = 0.01) [Table 1].